Indication
New-onset Type 1 Diabetes
1 clinical trial
1 product
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.Status: Terminated, Estimated PCD: 2023-04-27
Product
Ladarixin